fluorouracil and sorafenib

fluorouracil has been researched along with sorafenib in 101 studies

Research

Studies (101)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (5.94)	29.6817
2010's	80 (79.21)	24.3611
2020's	15 (14.85)	2.80

Authors

Authors	Studies
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Danielli, M; Giri, GF; Marinelli, RA; Spanevello, RA	1
Chen, J; Dai, H; Ge, S; Li, G; Ling, Y; Shi, Y; Ye, L	1
Mostafa, AS; Selim, KB	1
Akber Ansari, S; Arote, R; Chhajed, S; Pathan, SK; Patil, R; Sangshetti, J; Shinde, DB	1
Xu, Z; Zhang, L	1
Amen, Y; El-Sayed, MA; Kitamura, M; Okauchi, T; Othman, DIA; Selim, KB; Shimizu, K; Tantawy, AS	1
Liu, Y; Xu, Z; Zhao, SJ	1
Chen, W; Gu, X; Guan, M; Huang, X; Li, X; Qiu, J; Zhang, Y; Zhao, Y; Zhou, Q; Zou, Y	1
Gong, YP; He, ZX; Ma, LY; Zhang, X; Zhao, W	1
Kurjata, J; Piorecka, K; Stanczyk, WA	1
Escudier, B; Gore, ME	1
Curtiss, FR	1
Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM	1
Daher, IN; Yeh, ET	1
Qin, LX; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY	1
Andreu, J; Carles, J; Serrano, C; Suárez, C	1
Tai, CJ	1
Albanell, J; Bellmunt, J; Calvo, E; Carles, J; Lázaro, M; López, R; Pérez-Gracia, JL; Rubió, J; Trigo, JM; Virizuela, JA	1
Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY	1
Grossgoupil, M; Ravaud, A	1
Greten, TF; Manns, MP; Plentz, RR	1
Chang, HM; Choi, YH; Kang, BW; Kang, YK; Kim, C; Kim, TW; Lee, JL; Ryu, MH	1
Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ	1
Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N	1
Oberstein, PE; Saif, MW	1
Kim, DY	1
Eto, M; Inokuchi, J; Kiyoshima, K; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A	1
Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA	1
Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS	1
Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W	1
Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Navaraj, A; Smith, CD; Wang, W	1
Bartolozzi, C; Iannopollo, M; Lencioni, M; Oliveri, F; Orlandini, C; Petrini, I; Ricasoli, M; Ricci, S	1
Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M	1
Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S	1
Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B	1
Gradishar, WJ	1
Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY	1
Kaklamani, V; Raffin, M; Reddy, S	1
Kaneko, S; Yamashita, T	1
Allensworth, JL; Devi, GR; Diehl, AM; Lyerly, HK; Morse, MA; Rangwala, F; Smith, GR; Thomas, Z; Williams, KP	1
Berger, MR; Galle, PR; Gockel, I; Graf, C; Hainz, M; Hamdi, S; Maderer, A; Moehler, M; Schimanski, CC; Schmidtmann, I; Theobald, M; Wehler, TC	1
Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T	1
Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY	1
Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM	1
He, ZY; Hua, XD	1
Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S	1
Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W	1
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y	1
Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L	1
Shen, HJ; Wang, YH; Xu, J	1
Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M	1
Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M	1
Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W	1
Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE	1
Baracos, VE; Maia, YL; Ormsbee, M; Prado, CM; Sawyer, MB	1
Tan-Shalaby, J	1
Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL	1
Barnadas, A; Barriuso, J; Casado, E; Gallego, R; Garcia Foncillas, J; Garcia-Albeniz, X; Iranzo, V; Juez, I; Martin-Richard, M; Maurel, J; Pericay, C; Queralt, B; Saigi, E; Visa, L	1
Agostini, V; Andreone, P; Biasco, G; Bolondi, L; Brandi, G; Cucchetti, A; de Rosa, F; di Girolamo, S; Golfieri, R; Gramenzi, A; Pinna, AD; Sama, C; Serra, C; Trevisani, F	1
Deng, LF; Jia, QA; Li, JH; Ren, ZG; Shen, HJ; Sun, XJ; Wang, YH	1
Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK	1
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO	1
Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ	1
Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ	1
Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV	1
Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM	1
Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K	1
Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, M; Lee, S; Park, SY; Yoon, JH	1
Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J	1
Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X	1
Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Ogawa, H; Umeshita, K; Wada, H; Yamada, D; Yamashita, M	1
Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC	1
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K	1
Li, Q; Wen, F; Zhang, P	1
Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I	1
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S	1
Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L	1
Meyer, T	1
Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K	1
Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ	1
Clifford, R; Gollins, S; Govindarajah, N; Parsons, JL; Vimalachandran, D; West, NP	1
Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R	1
Goyal, L; Qadan, M; Zhu, AX	1
Burki, TK	1
He, M; Li, Q; Shi, M	1
Coriat, R; Dermine, S; Palmieri, LJ	1
Han, L; Li, T; Lin, Y; Ma, D; Ma, X; Qin, Z; Qiu, Y; Shen, X; Sun, C; Zhao, Y; Zhu, L	1
Kawagishi, N; Kimura, M; Kitagataya, T; Maehara, O; Mizokami, M; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Ohnishi, S; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Sugiyama, M; Suzuki, K; Takeda, H; Umemura, M; Yamada, R; Yamamoto, K	1
Fu, J; Wang, X; Yue, Q	1
Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ	1
Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y	1
Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY	1
Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M	1
Sidaway, P	1
Fujinaga, Y; Hokuto, D; Kawaratani, H; Kitagawa, K; Narita, H; Nishimura, N; Ozutsumi, T; Shibamoto, A; Sho, M; Takeda, S; Tsuji, Y; Yoshiji, H	1
Fang, X; Gong, L; Guan, XY; Lam, KO; Lam, RHW; Lee, AW; Liu, B; Luo, J; Ren, J; Tiu, YC; Yan, Q; Yang, Y; Zhang, Y	1
Attia, J; McKay, GJ; Oranratnachai, S; Rattanasiri, S; Raunroadroong, N; Sirachainan, E; Tansawet, A; Thakkinstian, A	1
Liu, D; Xu, M; Zhou, G	1

Reviews

14 review(s) available for fluorouracil and sorafenib

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review. Bioorganic & medicinal chemistry, 2019, 09-15, Volume: 27, Issue:18 Topics: Humans; Phthalazines	2019
Coumarin-containing hybrids and their anticancer activities. European journal of medicinal chemistry, 2019, Nov-01, Volume: 181 Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship	2019
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles	2019
Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Protein Binding; Protein Conformation; Proto-Oncogene Proteins c-met; Pyridazines; Pyrophosphatases; Structure-Activity Relationship	2021
Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art. Journal of medicinal chemistry, 2022, 09-08, Volume: 65, Issue:17 Topics: Acridines; Acriflavine; Anti-Bacterial Agents; COVID-19 Drug Treatment; Humans; Intercalating Agents; Neoplasms; SARS-CoV-2	2022
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5 Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Delivery Systems; Endpoint Determination; Floxuridine; Fluorouracil; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib; Survival Analysis; Treatment Outcome	2006
Vascular complications of selected cancer therapies. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases	2008
Molecular therapy of pancreatic cancer. Minerva endocrinologica, 2010, Volume: 35, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2010
Sorafenib in locally advanced or metastatic breast cancer. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles	2012
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib	2012
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics. Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:8 Topics: Antineoplastic Agents; Body Composition; Body Mass Index; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Niacinamide; Nutritional Status; Nutritional Support; Phenylurea Compounds; Sorafenib	2013
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis, 2014, Volume: 17, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2014
Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. The British journal of surgery, 2018, Volume: 105, Issue:12 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoadjuvant Therapy; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Rectal Neoplasms; Sorafenib	2018

Trials

27 trial(s) available for fluorouracil and sorafenib

Article	Year
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). The Lancet. Oncology, 2010, Volume: 11, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis	2010
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Stomach Neoplasms; Time Factors; Treatment Outcome	2012
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. American journal of clinical oncology, 2011, Volume: 34, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome	2011
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. Journal of clinical pharmacology, 2011, Volume: 51, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib	2011
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2012
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Treatment Outcome	2012
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2012
Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. Journal of clinical pharmacology, 2012, Volume: 52, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Israel; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vitamin B Complex	2012
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-01, Volume: 30, Issue:13 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Brazil; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib; Time Factors; Treatment Outcome	2012
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography	2013
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Investigational new drugs, 2013, Volume: 31, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome; Wisconsin	2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome	2013
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Oxonic Acid; Patient Compliance; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tegafur; Treatment Outcome	2014
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-01, Volume: 19, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Treatment Outcome	2013
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib	2013
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials, 2013, Jul-22, Volume: 14 Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Receptor, ErbB-2; Research Design; Sorafenib; Time Factors; Treatment Outcome	2013
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Investigational new drugs, 2013, Volume: 31, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Treatment Outcome	2013
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. The oncologist, 2013, Volume: 18, Issue:12 Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome	2013
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. Investigational new drugs, 2014, Volume: 32, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib	2014
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib	2015
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Investigational new drugs, 2016, Volume: 34, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome	2016
Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, Volume: 118, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Rectal Neoplasms; Sorafenib; Treatment Outcome	2016
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC cancer, 2018, Jun-04, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Sorafenib; Treatment Outcome	2018
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:3 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelling; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Portal Vein; Prospective Studies; Sorafenib; Survival Rate; Venous Thrombosis	2018
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA oncology, 2019, 07-01, Volume: 5, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult	2019
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. The oncologist, 2021, Volume: 26, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Sorafenib; Treatment Outcome	2021
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 02-10, Volume: 40, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mutation; Oxaliplatin; Progression-Free Survival; Sorafenib; Time Factors	2022

Other Studies

60 other study(ies) available for fluorouracil and sorafenib

Article	Year
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines. Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16 Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Glucose; Humans; Liver Neoplasms	2016
Synthesis and bioactivities of novel pyrazole oxime derivatives containing a 1,2,3-thiadiazole moiety. Bioorganic & medicinal chemistry letters, 2016, 09-15, Volume: 26, Issue:18 Topics: HCT116 Cells; Humans; Inhibitory Concentration 50; Oximes; Pyrazoles; Thiadiazoles	2016
Synthesis and anticancer activity of new dihydropyrimidinone derivatives. European journal of medicinal chemistry, 2018, Aug-05, Volume: 156 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrimidinones; TOR Serine-Threonine Kinases	2018
Design, Synthesis and Anticancer Evaluation of New Substituted Thiophene-Quinoline Derivatives. Bioorganic & medicinal chemistry, 2019, 10-01, Volume: 27, Issue:19 Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Caspase 9; Cell Proliferation; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Molecular Structure; Quinolines; Structure-Activity Relationship; Thiophenes	2019
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. European journal of medicinal chemistry, 2020, Nov-01, Volume: 205 Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Viral; Hepatitis B virus; Humans; Liver Neoplasms; Quinazolinones; Virus Replication	2020
Pharmacy benefit spending on oral chemotherapy drugs. Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7 Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States	2006
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11 Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea	2008
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-01, Volume: 15, Issue:15 Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Endoglin; Endothelium, Vascular; Fluorouracil; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Cell Surface; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor	2009
Acute aortic dissection during sorafenib-containing therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1 Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2010
Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma. Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:6 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine	2009
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. American journal of clinical oncology, 2011, Volume: 34, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure	2011
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy. The Lancet. Oncology, 2010, Volume: 11, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2010
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome	2011
Which treatment modality should we choose for advanced hepatocellular carcinoma? The Korean journal of hepatology, 2010, Volume: 16, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate	2010
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Female; Fluorouracil; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; Tegafur; Thymidylate Synthase	2011
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Female; Fluorouracil; Humans; Mice; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); Pyridines; Quinacrine; ras Proteins; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2011
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. Anticancer research, 2011, Volume: 31, Issue:11 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib; Treatment Outcome	2011
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-15, Volume: 18, Issue:14 Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome	2012
Targeting angiogenesis in metastatic breast cancer. The oncologist, 2012, Volume: 17, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC cancer, 2012, Sep-10, Volume: 12 Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Cell Survival; Drug Synergism; Enzyme Activation; Fluorouracil; Gene Expression Regulation, Enzymologic; Growth Inhibitors; Hep G2 Cells; Hepatic Stellate Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Thymidylate Synthase; Time Factors	2012
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. International journal of colorectal disease, 2013, Volume: 28, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Ki-67 Antigen; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays	2013
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. Anticancer research, 2012, Volume: 32, Issue:9 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thrombosis	2012
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Iodized Oil; Liver Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate	2012
The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. Digestive diseases and sciences, 2013, Volume: 58, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Fluorouracil; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; NF-E2-Related Factor 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib	2013
[Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:2 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Synergism; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Burden	2013
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. BMC cancer, 2013, Jul-29, Volume: 13 Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib	2013
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. The oncologist, 2013, Volume: 18, Issue:8 Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2013
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? BMJ case reports, 2013, Sep-16, Volume: 2013 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vitamin B Complex	2013
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. Journal of clinical gastroenterology, 2014, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome	2014
[Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2013, Volume: 21, Issue:11 Topics: Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Antagonism; Fluorouracil; Humans; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; STAT3 Transcription Factor	2013
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World journal of gastroenterology, 2014, Jan-07, Volume: 20, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome	2014
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Journal of gastroenterology, 2015, Volume: 50, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis	2015
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2. European urology, 2015, Volume: 68, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib	2015
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. Journal of digestive diseases, 2015, Volume: 16, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome	2015
Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling. Molecular medicine reports, 2015, Volume: 12, Issue:6 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorouracil; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-jun; Sorafenib	2015
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. International journal of oncology, 2016, Volume: 49, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucine; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib	2016
Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World journal of gastroenterology, 2016, Jun-21, Volume: 22, Issue:23 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Niacinamide; Off-Label Use; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Withholding Treatment	2016
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Anticancer research, 2016, Volume: 36, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome	2016
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Cohort Studies; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Monte Carlo Method; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib	2016
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. British journal of cancer, 2017, Dec-05, Volume: 117, Issue:12 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib	2017
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. Oncology, 2018, Volume: 94, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Retrospective Studies; Sorafenib; Survival Rate	2018
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Journal of hepatology, 2018, Volume: 69, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Immunosuppressive Agents; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Vitamin B Complex; Young Adult	2018
Sorafenib and hepatic arterial infusion chemotherapy: another failed combination. The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:6 Topics: Adult; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Liver Neoplasms; Sorafenib	2018
Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China. JAMA oncology, 2019, 07-01, Volume: 5, Issue:7 Topics: Carcinoma, Hepatocellular; China; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Vein; Sorafenib	2019
Hepatic arterial chemotherapy for hepatocellular carcinoma. The Lancet. Oncology, 2019, Volume: 20, Issue:6 Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Vein; Sorafenib	2019
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma-In Reply. JAMA oncology, 2019, 12-01, Volume: 5, Issue:12 Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Vein; Sorafenib	2019
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma. JAMA oncology, 2019, 12-01, Volume: 5, Issue:12 Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Vein; Sorafenib	2019
NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma. Journal of molecular medicine (Berlin, Germany), 2020, Volume: 98, Issue:2 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fluorouracil; Humans; Liver Neoplasms; Mice, Nude; Nod1 Signaling Adaptor Protein; Protein Kinase Inhibitors; Proto-Oncogene Mas; RNA, Small Interfering; Signal Transduction; Sorafenib; src-Family Kinases	2020
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. Carcinogenesis, 2021, 02-11, Volume: 42, Issue:1 Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fibroblast Growth Factor 2; Fibroblast Growth Factors; Fluorouracil; Humans; Liver Neoplasms; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays	2021
Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer. Biochemical and biophysical research communications, 2020, 09-03, Volume: 529, Issue:4 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Microfilament Proteins; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Sorafenib; Up-Regulation	2020
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. Drug design, development and therapy, 2020, Volume: 14 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Epirubicin; Female; Fluorouracil; Glycosides; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Sorafenib	2020
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Journal of cancer research and clinical oncology, 2021, Volume: 147, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Survival Rate	2021
HAIC-FO improves outcomes in HCC. Nature reviews. Clinical oncology, 2022, Volume: 19, Issue:3 Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Oxaliplatin; Sorafenib	2022
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report. Clinical journal of gastroenterology, 2022, Volume: 15, Issue:5 Topics: Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Interferons; Liver Neoplasms; Male; Portal Vein; Sorafenib; Thrombosis; Venous Thrombosis	2022
Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment. Hepatology communications, 2022, Volume: 6, Issue:11 Topics: Amino Acid Oxidoreductases; Collagen; Collagen Type I; Drug Resistance; Ecosystem; Fluorouracil; Humans; Integrins; Liver Cirrhosis; Liver Neoplasms; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein-Lysine 6-Oxidase; Receptor, Serotonin, 5-HT1A; rho-Associated Kinases; Sorafenib; Tumor Microenvironment	2022
Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors. Cancer medicine, 2023, Volume: 12, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Retrospective Studies; Sorafenib; Treatment Outcome	2023
Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA. Nutrition and cancer, 2023, Volume: 75, Issue:5 Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorouracil; Humans; Kidney Neoplasms; Mice; rhoA GTP-Binding Protein; Sorafenib	2023